Developing new antibiotics to fight resistant bacterial infections
Official title: Evaluation of Streptamine Analogs to Overcome Resistance to Apramycin
Funded at University of Georgia · NIH-10738751 · Data updated 2026-11-12
This study is working on improving a new antibiotic called apramycin to help fight tough bacterial infections that don't respond to regular treatments, especially for people dealing with multidrug-resistant infections.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project start | November 10, 2022 |
| Project end | October 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $205,033 |
| NIH project number | 5R21AI172807-02 |
| Project ID | NIH-10738751 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients suffering from multidrug-resistant bacterial infections, particularly those caused by Gram-negative bacteria.
✕Less likely to help
Patients with infections caused by bacteria that are not resistant to current antibiotics may not benefit from this research.
What this research studies
This research focuses on creating advanced versions of apramycin, a novel antibiotic, to combat bacterial infections that have become resistant to current treatments. The approach involves modifying the chemical structure of apramycin to enhance its effectiveness against specific resistance mechanisms. By testing these new analogs, the research aims to provide solutions for treating multidrug-resistant Gram-negative infections, which are a significant challenge in healthcare today.
Why it matters
Potential benefit: If successful, this research could lead to new antibiotics that effectively treat infections resistant to existing medications.
How similar studies have gone: Previous research has shown promise in developing new antibiotics to overcome resistance, indicating that this approach could yield significant advancements.
Where this research is happening
-
University of Georgia
Athens, United States Active
Researchers
- Principal investigator: Crich, David — University of Georgia
- Study coordinator: Crich, David
Related research
Other NIH-funded projects on the same topics.
-
BRD4 and NIPBL work together to control facial bone development
A study in mice and cell models will explore how BRD4 and NIPBL work together to control how genes are turned on in facial development, which could clarify causes of craniofacial disorders.
-
Sulfated glycosaminoglycan hydrogels to protect brain volume after traumatic injury
A new implantable gel made from specially sulfated sugars may help prevent brain shrinkage and improve function after a serious brain injury.
-
Understanding how Kaposi’s sarcoma virus switches on late genes during infection
Scientists are studying how the virus causing Kaposi’s sarcoma turns on late genes when its DNA copies itself, which could reveal new ways to treat cancer in people with AIDS.
-
Understanding how cells control signals and adhesion with the secretory pathway
A funded NIH project looks at how the cell’s secretory system shapes signals, receptors, and attachment to the outside of the cell, which can influence many human diseases.
-
AI-powered math and machine learning for bioscience and drug discovery
A broad NIH grant supports using advanced math and AI to better predict viral variants and aid drug discovery, with the goal of helping patients by accelerating pandemic response.
-
AI-driven platform to predict vaccine-escape variants and design mutation-proof antibodies
An AI-powered approach aims to anticipate SARS-CoV-2 variants that may dodge vaccines and to create antibodies that stay effective.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.